Literature DB >> 8144953

TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.

H Yamamoto1, M Hirayama, C Genyea, J Kaplan.   

Abstract

In addition to generating cells with non-MHC-restricted cytotoxic activity that is characteristic of lymphokine-activated killer (LAK) cells, in vitro cultures of lymphocytes with relatively high concentrations of IL-2 generate cells that simultaneously exhibit two distinct types of suppressor activities: veto, the ability of cells to specifically suppress generation of allo-CTL against their own histocompatibility Ags; and natural suppression, the ability of these same cells to nonspecifically suppress the generation of allo-CTL against both their own and unrelated cell surface Ags. In contrast to veto, which is known to require cell-cell contact between veto-active cells and precursors of CTL, natural suppression is known to be mediated by soluble factors. To identify and characterize suppressor factors that might mediate the natural suppressor activity of IL-2-activated lymphocytes, murine spleen cells were cultured with 1000 U/ml IL-2, and, after varying periods of incubation, their LAK cytolytic activity and natural suppressor activity was determined and cell supernatants were collected and tested for their effects on mixed lymphocyte culture-induced generation of allo-CTL. Like the IL-2-activated lymphocytes themselves, supernatants of these cells nonspecifically inhibited mixed lymphocyte culture-induced generation of allo-CTL. Rabbit anti-TGF-beta specifically neutralized the suppressive effects of both LAK cell supernatants and the IL-2-activated lymphocytes themselves. These findings indicate that TGF-beta is the primary mediator of the natural suppressor activity of IL-2-activated lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144953

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.

Authors:  O Asai; D L Longo; Z G Tian; R L Hornung; D D Taub; F W Ruscetti; W J Murphy
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

2.  Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro.

Authors:  H M Diepolder; M C Jung; E Wierenga; R M Hoffmann; R Zachoval; T J Gerlach; S Scholz; G Heavner; G Riethmüller; G R Pape
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro.

Authors:  T Kanto; T Takehara; K Katayama; A Ito; K Mochizuki; N Kuzushita; T Tatsumi; Y Sasaki; A Kasahara; N Hayashi; M Hori
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

4.  Human allograft acceptance is associated with immune regulation.

Authors:  A M VanBuskirk; W J Burlingham; E Jankowska-Gan; T Chin; S Kusaka; F Geissler; R P Pelletier; C G Orosz
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

5.  Inhibition of cytotoxic alloreactivity by human allogeneic mononuclear cells: evidence for veto function of CD2+ cells.

Authors:  G Raddatz; A Deiwick; T Sato; H J Schlitt
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

6.  Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.

Authors:  K E Balashov; S J Khoury; D A Hafler; H L Weiner
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

7.  Cross-linking of Fc(gamma)-receptor on monocytes inhibits hepatitis C virus-specific cytotoxic T-lymphocyte induction in vitro.

Authors:  T Kanto; N Hayashi; T Takehara; K Katayama; A Ito; K Mochizuki; N Kuzushita; T Tatsumi; Y Sasaki; A Kasahara; M Hori
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

8.  A transforming growth factor beta-like immunosuppressive factor in immunoglobulin G-binding factor.

Authors:  C Bouchard; A Galinha; E Tartour; W H Fridman; C Sautès
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

Review 9.  The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases.

Authors:  David A Horwitz; J Dixon Gray; Song Guo Zheng
Journal:  Arthritis Res       Date:  2002-03-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.